Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Cancer Immunol Immunother. 2015 Sep 21;64(12):1531–1539. doi: 10.1007/s00262-015-1758-5

Table 3.

Multivariate analysis of key parameters and clinical outcomes

Parameter Hazard Ratio (DFS) P- value (DFS) Hazard Ratio (OS) P- value (OS)
Stagea 0.58b 0.21b
    III 1.3 0.32 1.4 0.3
    IV 1.3 0.35 0.87 0.75
    III vs IV 1.0 0.91 0.6 0.12
Gender 0.76 0.12 0.66 0.07
Age 1.03 0.90 1.26 0.39
Immune Response 0.93 0.69 1.05 0.83
a

The reference group is patients with Stage II melanoma unless otherwise stated.

b

Cumulative P-value for all stages.